Our coating technology is an important tool in the global fight against antimicrobial resistance and prevents bacteria from adhering to the surface of a medical device. When fewer bacteria attach, the risk of biofilm formation and subsequent infection is significantly reduced. Our technology repels bacteria rather than eliminates. More than 230 million Bactiguard coated catheters have been sold so far, and more than 40 clinical studies have been performed involving more than 100,000 patients, who have used products featuring Bactiguard’s coating technology. It is clinically proven that the technology is safe and biocompatible, and significantly reduces the risk of medical device related infections.

We are in a strong expansion phase in the markets in the US, Europe, China, India, Southeast Asia and the Middle East.

Our headquarters and our production facilities are located in Stockholm as well as  Tullinge, Penang and Senai in Malaysia. Bactiguard is listed on Nasdaq Stockholm in the mid-cap segment.